ArticleCell communication and signaling : CCS2025
USP13 promotes colorectal cancer progression by deubiquitinating and stabilizing HIF-1α.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TMC7 promotes colorectal cancer metastasis via inhibition of PKN2 and regulation of hypoxia-adaptive responses.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypoxia-inducible factor-1α (HIF-1α) is a key transcriptional regulator in tumor progression, tightly controlled by ubiquitination-mediated proteasomal degradation. While multiple deubiquitinases (DUBs) stabilize HIF-1α, the role of ubiquitin specific peptidase 13 (USP13) in colorectal cancer (CRC) remained undefined. This study aimed to elucidate whether USP13 regulates HIF-1α stability and contributes to CRC pathogenesis.
methodsUSP13-HIF-1α interaction was assessed via co-immunoprecipitation (co-IP), immunofluorescence, and domain mapping. Ubiquitination assays evaluated USP13-mediated HIF-1α deubiquitination using K-specific ubiquitin mutants. Functional impacts were tested in CRC cell lines using CRISPR/Cas9-mediated USP13 knockout and overexpression. In vitro assays included proliferation (CCK-8), colony formation, migration, invasion, and angiogenesis (HUVECs tube formation). In vivo relevance was validated in xenograft models, USP13-knockout mice, and an AOM/DSS-induced CRC model. Clinical correlation used IHC staining of CRC patient tissues and TCGA data analysis.
resultsUSP13 directly bound HIF-1α via its C-terminal UBA domain, cleaving K48-linked polyubiquitin chains to stabilize HIF-1α and enhance its transcriptional activity. USP13 knockout reduced HIF-1α levels, suppressed CRC cell proliferation, migration, invasion, and angiogenesis in vitro, and attenuated tumor growth in xenografts. Conversely, USP13 overexpression exacerbated these effects. Clinically, USP13 and HIF-1α levels correlated positively in CRC tissues and with Ki-67 expression. USP13 deficiency in mice reduced tumor burden in AOM/DSS models, decreased vascular density (CD31+), and downregulated VEGFA/Ki-67. Rescue experiments confirmed HIF-1α dependency for USP13-mediated oncogenic effects.
conclusionsUSP13 promotes CRC progression by deubiquitinating and stabilizing HIF-1α, driving tumor growth, metastasis, and angiogenesis. This identifies USP13 as a pro-tumorigenic factor and potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.